Volume 19, Number 3—March 2013
CME ACTIVITY - Research
Clinical and Therapeutic Features of Pulmonary Nontuberculous Mycobacterial Disease, Rio de Janeiro, Brazil
Table 6
Treatment regimens for all patients with ATS-defined PNTM, per infecting species, Brazil, 1993–2011*
Species | Treatment regimen (%)† |
---|---|
Mycobacterium avium complex | Clarithromycin, amikacin,ethambutol, rifampin (54.7) |
Clarithromycin, ethambutol,quinolone, terizidon (28.3) | |
Clarithromycin, amikacin, ethambutol, quinolone‡ (17.0) |
|
Mycobacterium kansasii | Rifampin, ethambutol, isoniazid (52.5) |
Rifampin, ethambutol, isoniazid, clarithromycin, amikacin (47.5) |
|
M. abscessus | Clarithromycin, amikacin (68.4) |
Clarihromycin, amikacin, doxycycline (10.5) | |
Clarithromycin, amikacin, terizidon (21) |
|
M. massiliense | Clarithromycin, amikacin (33.3) |
Clarithromycin, amikacin, terizidon (33.3) | |
Clarithromycin, amikacin, imipenem, tigeciclin (33.3) |
|
M. fortuitum | Clarithromycin, amikacin, quinolone (64.2) |
Clarithromycin, amikacin, terizidon (28.5) | |
Clarithromycin, amikacin, quinolone, doxycycline (7.3) |
*ATS, AmericanThoracic Society; PNTM, pulmonary nontuberculous mycobacterial disease.
†Median duration of treatment, 19 mo.
‡Quinolones: levofloxacin, ciprofloxacin, moxifloxacin, ofloxacin.